Gradalis is dedicated to developing and commercializing “molecular” based personalized therapeutics that are tumor specific, more effective and less toxic than current treatment modalities.

Gradalis Announces Research Alliance with Mount Sinai Gradalis Announces Research Alliance with Mount Sinai
A Statement From Gradalis A Statement Regarding Ewing's Sarcoma Trial
Dr. Brian Daniels joins the SAB Gradalis Announces the Appointment of Dr. Brian Daniels to the Newly Formed Scientific Advisory Board
Dr. Steven Burakoff Joins Gradalis SAB Appointment of Dr. Steven Burakoff to the Gradalis Scientific Advisory Board
Gradalis to Participate in iC3 Life Science Summit Gradalis to Participate in 2nd Annual iC3 Life Science Summit Hosted By BioNorthTX
Bio Investor Forum Press Release Gradalis to Take Part in BIO Investor Forum in San Francisco
SAB Formation Press Release Sir Marc Feldmann to Chair Gradalis Scientific Advisory Board
Vigil®
Immunotherapies
Goal

 

 

 
Published on Dec 18, 2013

Carley Rutledge is studying biology at university in Colorado. She loves hiking and hanging out with friends. Many of us take these things for granted, but for Carley they are only possible because she's taking part in a trial for a cancer vaccine. Without the trial, Carley would have been stuck in hospital having a second round of chemotherapy. Carley tells her story in this film. We also hear from her doctors, who are pioneering this new personalized cancer treatment that uses a patient's own immune system to fight the disease.